Johnson & Johnson JNJ

$256.48 -1.97 (-0.76%)

Valuation

Market cap
613,993,792,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.29
Forward PE
21.92
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
6,172,700
Avg volume
6,614,212
Day's range
$251.95 – $257.80
Shares out
2,409,898,000
Stochastic %K
32%
Beta
0.21
Analysts
Strong Sell
Price target
$282.60

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

JCJustCharting Oct 8, 9:53 PM
$SPY buy healthcare biotech that are profitable during red market $ABBV $LLY $JNJ
0 replies
Millionaire11 Oct 8, 7:12 PM
$CMPS $JNJ do it. We want $55 a share.
0 replies
pilobious Oct 8, 3:38 PM
$JNJ why the beatdown three days before an earnings release?
0 replies
ElliottwaveForecast Oct 8, 4:38 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 replies
Broview Oct 8, 4:21 AM
$JNJ boring but hold forever?
0 replies
Pope_of_Profit Oct 7, 4:09 PM
$JNJ correction probably over, I don't like to swing into ERs but might make an exception here
0 replies
Gebinator Oct 7, 3:17 PM
$SLS $JNJ $MRK $ABBV It's worth noting today $ABBV reached an all-time high on news of breakthrough therapy designations for its ADC drug candidates. With an MC verging on a half-trillion dollars, I would accept a stock-swap of some sort with $ABBV for the whole $SLS enchilada. Of course, the same goes for $JNJ, $MRK or any dark horse such as $LLY. Regardless of who and exact circumstances -- my final BO expectation remains ~ $40 Billy 🦖 MINIMUM
1 replies
E458 Oct 7, 2:13 PM
$SPY looks like $JNJ struggling with 260 and we may lose healthcare greenies soon
0 replies